Merck Reports Q3 Loss, Raises Revenue Outlook and Cuts EPS Guidance
Merck reported a non-GAAP loss of $0.13 per share, including a $2.31 per-share charge related to its Terns Pharmaceuticals acquisition. It raised 2026 revenue guidance to $66.3 billion-$67.3 billion and lowered adjusted EPS guidance to $2.66-$2.76. Keytruda and Keytruda QLEX revenue rose 5.2% year over year to $8.37 bi